Condition: Solid Tumor, Adult · Advanced Solid Tumor · Advanced Renal Cell Carcinoma · Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
This is an open label, single-arm, multicentre dose escalation (Part 1) and dose expansion (Part 2) study to evaluate different combinations of 3 radioactive dose levels of 177Lu-TLX250 administered intravenously with 3 different doses of peposertib in patients with CAIX-expressing solid tumors.
This description comes directly from the study's public registry record.
MEDICAL DIRECTOR, MD
Always discuss trial participation with your own doctor first.
| Macquarie University | North Ryde, New South Wales, Australia | Recruiting |
| Ashford (Icon) Cancer Centre | Adelaide, Australia | Recruiting |
| Princess Alexandra Hospital | Brisbane, Australia | Recruiting |
| Austin Health | Melbourne, Australia | Recruiting |
| GenesisCare Murdoch | Perth, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05868174